FDA touts cannabis scheduling work in new report on priorities • In Ukraine, President Zelensky signs medical cannabis bill into law • & more …
An excerpt from recent editions of the Cannabis Wire Daily newsletter.
FDA Looks Back On Fifty Years of Cannabis Research, Prepares for Growth Ahead
FDA researchers published an article this week titled “From Our Perspective: FDA’s 50 Years of Experience with Cannabis Research Helping to Support Tomorrow’s Cannabis Drug Development.”
Cannabis comes up at FDA listening session on tobacco • A GOP pushback on rescheduling • NY lawmakers push Hochul on tribal sales bill • & more …
An excerpt from recent editions of the Cannabis Wire Daily newsletter.
Congressional Research Service pubs primer on the FDA, hemp • RFI on CBD closed. Here’s a look at submissions • New York litigation latest • & more …
An excerpt from recent editions of the Cannabis Wire Daily newsletter.
Congress Picks Up the Baton from the FDA on CBD, Seeking Data
The unregulated hemp-derived cannabinoid marketplace has exploded since the 2018 Farm Bill descheduled hemp. The FDA has asked Congress to help with a “new regulatory pathway.”
NHTSA to ramp up DRE data collection • Virginia regulators prep for medical cannabis market study • FDA issues delta-8 THC warnings • & more …
An excerpt from recent editions of the Cannabis Wire Daily newsletter.
As FDA Looks to Congress for CBD Regs, it Elaborates on Potential Paths Forward
On Thursday, the FDA pushed its desire to work with Congress on cannabinoid product rules, including delta-8 THC.
CBD’s Potential for Reproductive Harms Among “Big Reasons” Behind FDA’s Punt on Rules
The FDA is seeking a “harm reduction framework” as it works with Congress on a path for CBD, according to the agency’s Cannabis Product Committee lead.
Health Canada gives $1M to Canadian Schizophrenia Society for cannabis work • House cmte. investigates FDA on CBD • A letter to Biden on descheduling • & more …
An excerpt from a recent edition of the Cannabis Wire Daily newsletter.